Randomised controlled trial: Liraglutide for weight loss: more research is needed.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

1. Naltrexone HCI/bupropion HCI for chronic weight management in obese adults: patient selection and perspectives.Patient preference and adherence · 2016
   Review
2. Treatment options for obesity and potential therapies on the horizon.P & T : a peer-reviewed journal for formulary management · 2011
   Article

Corrections and comments

• Comment on
  Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.2009

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.